Parenteral immunization induces mucosal protection: A challenge to the mucosal immunity paradigm

Mucosal Immunology, Two-Volume Set

Volumn , Issue , 2005, Pages 831-840

  Underdown, Brian J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947402861     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012491543-5/50049-8     Document Type: Chapter

References (111)

1. Ahmed A., Bhattacharjee A.K., Mosley W.J. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and nonendemic cholera areas. J. Immunol. 1970, 105:431-441.
2. Andre F.E. Approaches to a vaccine against hepatitis A: Development and manufacture of inactivated vaccine. J. Infect. Dis. 1995, 171:S33-S39. Suppl.
3. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 1970, 282:417-420.
4. Balmer P., Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 2002, 51:717-722.
5. Banatvala J.E., Best J.M., O'Shea S., Waldman R.H. Rubella immunity gap: is intranasal vaccination the answer?. Lancet 1979, 1:970.
6. Barbour M.L., Mayon-White R.T., Coles C., Crook D.W.M. The impact of conjugate vaccine on carriage of haemophilus influenzae type b. J. Infect. Dis. 1995, 171:93-98.
7. Barbour M.L. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg. Infect. Dis. 1996, 2:176-182.
8. Black S., Shinefield H. Safety and efficacy of the sevenvalent pneumococcal conjugate vaccine: evidence from Northern California. Eur. J. Pediatr. 2002, 161(Suppl 2):S127-S131.
9. Blackwelder W.C., Storsaeter J., Olin P., Hallander H.O. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am. J. Dis. Child. 1991, 145:1285-1289.
10. Borrow R., Fox A.J., Cartwright K., Begg N.E., Jones D.M. Salivary antibodies following parenteral immunization of infant with a meningococcal serogroup A and C conjugated vaccine. Epidemiol. Infect. 1999, 123:201-208.
11. Bose A., Coen P., Tully T., Viner R., Booy R Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet 2003, 391:675-676.
12. Brokstad K.A., Cox R.J., Olofsson J., Jonsson R., Haaheim L.R. Parenteral influenza vaccination induces a rapid systemic and local immune response. J. Infect. Dis. 1995, 171:198-203.
13. Brokstad K.A., Eriksson J.C., Cox R.J., Tynning T., Ollofsson J., Jonsson R., Davidson A. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosae. J. Infect. Dis. 2002, 185:878-884.
14. Butcher E.C., Picker L.J. Lymphocyte homing and homeostasis. Science 1996, 272:60-66.
15. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 1986, 24:157-160.
16. Cohen D., Green M.S., Block C., Slepon R., Ofek I. A prospective study on the association between serum antibodies to lipopolysaccharide and attack rate of shigellosis. Clin. Microbiol. 1991, 29:386-389.
17. Cohen D., Ashkenazi S., Green M.S., Gdalevich M., Robin G., Slepon R., Yavzori M., Orr N., Block C., Ashkenazi I., Shemer J., Taylor D.N., Hale T.L., Sadoff J.C., Pavilakova D., Schneerson R., Robbins J.B. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997, 349:155-159.
18. Cohen M.B., Giannella R.A., Bean J., Taylor D.N., Parker S., Hoeper A., Wowk S., Hawkins J., Kochi S.K., Schiff G., Killeen K.P. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun. 2002, 70(4):1965-1970.
19. Conner M.E., Crawford S.E., Barone C., O'Neal C., Zhou Y.J., Fernandez F., Parwani A., Saif J., Cohen J., Estes M.K. Rotavirus subunit vaccines. Arch. Virol. 1996, 12:199-206. (suppl.).
20. Conner M.E., Matson D.O., Estes M.K. Rotavirus vaccines and vaccination potential. Rotaviruses 1994, 286-337. Springer-Verlag, Berlin. R. Ramig (Ed.).
21. Couch R.B., Kasel J.A., Six H.R., Cate T.R. The basis for immunity to influenza in man. Genetics Variation among Influenza Viruses. ICN-UCLA Symposia on Molecular and Cellular Biology 1981, xxi:535. Academic Press, New York. D. Nayak, C.F. Fox (Eds.).
22. Dagan R., Melamed R., Muallem M., Piglansky L., Greenberg D., Abramson O., Mendelman P.M., Hohidar N., Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 1996, 174:1271-1278.
23. Dagan R., Fraser D. Conjugate pneumonococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr. Infect. Dis. J. 2000, (Suppl 19):S79-S87.
24. Darkes M.J., Plosker G.L. Pneumococcal conjugate vaccine (Prevnar, PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr. Drugs 2002, 4:609-630.
25. Davis W.J., Larson H.E., Simsarian J.P., Parkman P.D., Meyer H.M. A study of rubella immunity and resistance to infection. JAMA 1971, 215:600-608.
26. Deen J.L., Mink C.M., Cherry J.D., Christenson P.D., Pineda E.F., Lewis K., Blumberg D.A., Ross L.A. Household contact study of Bordetella pertussis infections. Clin. Infect. Dis. 1995, 21:1211-1219.
27. Demicheli V., Rivetti D., Deeks J.J., Jefferson T.O. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2001, 4:CD001269.
28. Dupont H.L. Shigella species: bacillary dysentery. Principles and Practice of Infectious Disease 1990, 1716-1722. Churchill-Livingstone, London. G.L. Mandell, R.G. Douglas, J.E. Bennett (Eds.).
29. El-Madhun A.S., Cox R.J., Soreide A., Oloffson J., Haaheim L.R. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J. Infect. Dis. 1998, 178:933-939.
30. Engstrom P.E., Gustafson, Granberg M., Engstron G.N. Specific IgA subclass responses in serum and saliva: a 12-month follow-up study after parenteral booster immunization with tetanus toxoid. Acta Odontol. Scand. 2002, 60:198-202.
31. Felix P., Pitt R. A new antigen of B. typhosus, its relation to virulence and in active and passive immunization. Lancet 1934, 2:186-191.
32. Fogel A., Gerichter C., Barnea B., Handsher R., Heeger E. Response to experimental challenge in persons immunized with different rubella vaccines. J. Pediatrics 1978, 92:26-29.
33. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Bell T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 1992, 326:663-667.
34. Giebink G.C. The prevention of pneumococcal disease in children. N. Engl. J. Med. 2001, 345:1177-1183.
35. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus-I. The role of humoral antibodies. J. Exp. Med. 1969, 129:1307-1326.
36. Gorse G.J., Otto E.E., Powers D.C., Chambers G.W., Eickhoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. 1996, 173:285-290.
37. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus-V. The effect of immunization with meningococcal group C polysaccharide vaccine. J. Exp. Med. 1969, 129:1385-1395.
38. Granstrom M., Olinder-Nielsen A.M., Holmbad P., Marks A., Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet 1991, 33:1230-1232.
39. Groothuis J.R., Simoes E.A.F., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., Arrobio J., Meissner H.C., Fulton D.R., Welliver R.C., Tristram D.A., Siber G.R., Prince G.A., Van Raden M., Hemming V.G. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 1993, 329:1524-1527.
40. Gupta R.K., Taylor D.N., Bryla D.A., Robbins J.B., Szu S.C. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect. Immun. 1998, 66(7):3095-3099.
41. Herremans T.D., Reimerink J.H., Buisman A.M., Kimman T.G., Loopmans M.P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J. Immunol. 1999, 162:5011-5018.
42. Kauppi M., Eskola J., Kayhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr. Infect. Dis. J. 1995, 14:286-294.
43. Keren D.F., McDonald R.A., Carey J.L. Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri. Infect. Immun. 1988, 56:910-915.
44. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., Parrot R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969, 89:422-434.
45. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.S., Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 2002, 347:1645-1651.
46. Landy M. Studies on Vi antigen: Immunization of human beings with purified Vi Antigen. Am. J. Hygiene 1964, 60:62.
47. Lahn M.N., Phan V.B., Vo A.H., Tran C.T., Lin F.Y., Bryla D.A., Chu C., Schiloach J., Robbins J.B., Schneerson R., Szu S.C. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 2003, 239:1390-1391.
48. Ledon T., Valle E., Valmaseda T., Cedre B., Campos J., Rodriguex B.D., M K., Garcia H., Carcia L., Fando R. Construction and characterisation of O139 cholera vaccine candidates. Vaccine 2003, 21:1282-1291.
49. Levine M.M., Kapper J. Live vaccines against cholera: an update. Vaccine 1993, 11:207-212.
50. Liang W., Wang S., Y F., Zhang L., Qi G., Liu Y., Gao S., Kan B. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect. Immun. 2003, 71:5498-5504.
51. Lin Feng Ying C., Ho V.A., Khiem H.B., Trach D.D., Bay Ph.Vn., Thanh T.C., Kozzaczka Z., Bryla D.A., Shiloach J., Robbins J.B., Schneerson, Szu S.C. The efficacy of a Salmonella typhi vi conjugate vaccine in two-five-year old children. N. Engl. J. Med. 2001, 344:1263-1269.
52. Losonsky G.A., Yunyongying J., Lim V., Reymann M., Lim Y.L., Wasserman S.S., Levine M.M. Factors influencing secondary vibriocidal immune responses: Relevance for understanding immunity to cholera. Infect. Immun. 1996, 64:10-15.
53. Luchner L.A., Reeves M., Hennessy T., Levine O.S., Popovic T., Rosenstein N., Parkinson J. Infect. Dis. 2002, 186:958-965.
54. Makela P.H., Kayhty H. Evolution of conjugate vaccines. Expert Rev. Vaccines 2002, 1:399-410.
55. Marine W.M., Chin T.D.Y., Gravelle C.R. Limitation of fecal and pharyngeal poliovirus excretion in salk-vaccinated children. Am. J. Hyg. 1962, 76:173-195.
56. Matter L., Kogelschatz K., Germann D. Serum levels of rubella virus antibodies indicating immunity: Response to vaccination of subjects with low or undetectable antibody concentrations. J. Infect. Dis. 1997, 175:749-755.
57. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman O.P. Immunogenicity and impact on nasopharyngeal carriage of a nonvalent pneumococcal conjugate vaccine. J. Infect Dis. 1999, 180:1171-1176.
58. McDermott M.R., Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory and genital tissues. J. Immunol. 1979, 122:1892-1898.
59. McVernon J., Andrews N., Slack M.P.E., Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b(Hib) combination vaccines with acellular pertussis. Lancet 2003, 361:1521-1523.
60. Millar E.V., O'Brian K.L., Levine O.S., Kvamme S., Reid R., Santosham M. Carriage disease among high risk American Indian children. Am. J. Public Health 2000, 90:1550-1554.
61. Millar E.V., O'Brien K.L., Watt J.P., et al. Duration of protection against pneumococcal nasopharyngeal carriage by 7-valent pneumococcal conjugate vaccine (pNCRM7) in Navajo and Apache children. Abstracts of ISPPD-2202, the 3rd International Symposium on Pneumococci and Pneumococcal diseases 2002.
62. Moldoveanu Z., Clement M.L., Primie S.J., Murphy B.R., Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995, 13:1006-1012.
63. Murdin A.D., Barreto L., Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996, 14:735-746.
64. Myers P.G. Intussusception, rotavirus and oral vaccines: summary of a workshop. Pediatrics 2002, 110:e17.
65. Neilsen A., Larsen S.O. Epidemiology of pertussis in Denmark: the impact of herd immunity. Int. J. Epidemiol. 1994, 23:1300-1307.
66. Nichol K.L., Lind A., Margolis K.L. The effectiveness of vaccination against influenza in healthy working adults. N. Engl. J. Med. 1995, 333:889-893.
67. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., van der Linden H.C., Voorhorst F.J., Kenemans P., Meijer C.J. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20-25.
68. Nieminen T., Kayhty H., Leroy O., Eskola J. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr. Infect Dis. J. 1999, 18:764-772.
69. Nordin J., Mullooley J., Pobledte S., Strikas R., Petrucci R., Wei F., Rush B., Safirstein B., Wheeler D., Nichol L.D. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York and Oregon: data from 3 healthy plans. J. Infect. Dis. 2001, 184:665-670.
70. Obaro S., Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J. Microbiol. 2002, 51:98-104.
71. O'Brien K. Disease transmission, routes, contributing factors and herd immunity. IJCP Suppl. 2001, 118:5-7.
72. Ogra P.L., Kerr-Grant D., Umana G., Dzierba J., Weintraub D. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. N. Engl. J. Med. 1971, 285:1333-1339.
73. Ogra P.L. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines. Ann. N.Y. Acad. Sci. 1995, 754:97-107.
74. Olin P. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: pertussis vaccination. Ann. N.Y. Acad. Sci. 1993, 754:273-277.
75. Olin P., Hallander H.O., Gustafsson L., Reizenstein E., Storsaeter J. How to make sense of pertussis immunogenicity data. Clin. Infect. Dis. 2001, 33(Suppl 4):S288-S291.
76. Olin P., Gustafsson L., Barreto L., Hessel L., Mast T.C., Rie A.V., Bogaerts H., Storsaeter J. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003, 21:17-18.
77. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J. Infect. Dis. 1991, 163:1-6.
78. Palmu A.A., Kaijalainen T., Verho J., Herva E., Makela P.H., Kilpi T.M. Long-term efficacy of the sevenvalent PncCRN vaccine on nasopharyngeal carriage. Abstracts of ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases 2002.
79. Petola H., Kilpi T., Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 1992, 340:592-594.
80. Pichichero M.E., Insel R.A. Mucosal antibody response to parenteral vaccination with Haemophilus influenzae type b capsule. J. Allergy Clin. Immunol. 1983, 72:481-486.
81. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., Wallace D., Kopp W., Adesberger J.W., Baseler M.W., Berzofsky J.A., Hildesheim A. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 2003, 188:327-338.
82. Plotkin S.A., Bouveret-LeCam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch. Intern. Med. 1995, 155:2293-2299.
83. Plotkin S.A., Farquhar J.D., Ogra P.L. Immunologic properties of RA27/3 rubella virus vaccine. JAMA 1973, 225:585-590.
84. Plotkin S.A. Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis. Rev. Med. Virol. 1997, 7:75-81.
85. Powers D.C., Gorse G.J., Otto E.E., Chambers G.W., Eichoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. 1996, 173:285-290.
86. Preston N.W. Why the rise in Haemophilus Influenza type b infections?. Lancet 2003, 362:330-331.
87. Reingold A.L., Hightower A.W., Bolan G.A., Jones E.E., Tiendrebeogo H., Broome C.V., Ajello G.W., Adamsbaum C., Phillips C., Yada A. Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985, 20:114-118.
88. Renegar K.B., Small P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 1991, 146:1972-1978.
89. Robbins J.B., Schneerson R., Anderson P., Smith D.H. The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 1996, 276:1181-1185.
90. Robbins J.B., Schneerson R., Szu S.C., Yang Y.H. Prospects for polysaccharide-protein conjugate vaccines. Ann. Sclavo. Collano. Monogr. 1986, 3:213-232.
91. Robbins J.B., Schneerson R., Szu S.C. Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 1995, 171:1387-1398.
92. Ruggeberg J., Heath P.T. Safety and efficacy of meningococcal group C conjugate vaccine. Expert Opin. Drug. Saf. 2003, 2:7-19.
93. Ryan E.T., Calgerwood S.B. Cholera vaccines. Clin. Infect. Dis. 2000, 31(2):561-565.
94. Sack D.A. Cholera control. Lancet 1994, 344:616-617.
95. Salerno-Goncalves R., Wyant T.L., Pasetti M.F., Fernandez-Vina M., Tacket C.O., Levine M.M., Sztein M.B. J. Immunol. 2003, 170:2734-2741.
96. Salk J., Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195:834-847.
97. Sansonetti P. Host-pathogen interactions: the seduction of molecular cross tal. Gut 2002, 50(Suppl 3):1112-1118.
98. Siber G.R., Thompson C., Reid G.R., Almeido-Hill J., Zacher B., Wolff M., Santosham M. Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease. J. Infect. Dis. 1992, 165(Suppl 1):S129-S133.
99. Silfverdal S.A., Bodin L., Olcén P. Why the rise in Haemophilus influenzae type b infections?. Lancet 2003, 362:331.
100. Stapleton J.T., Lange D.K., LeDuc J.W., Binn L.N., Jansen R.W., Lemon S.M. The role of secretory immunity in hepatitis A virus infection. J. Infect. Dis. 1991, 163:7-11.
101. Snydman D.R., Werner B.G., Heinze-Lacey B., Berardi V.P., Tilney N.L., Kirkman R.L., Milford E.L., Cho S.I., Bush H.L., Levey A.S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 1987, 317:1049-1054.
102. Snydman D.R. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev. Infect. Dis. 1990, 12(suppl 7):S839-S848.
103. Stanberry L.R., Spruance Sp.L., Cunningham A.L., Bernstein D.I., Mindal A., Sacks S., Tyring S., Aoki F.Y., Saloui M., Denis M., Vanderpapeliere P., Dubin G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002, 347:1652-1661. For the GlaxoSmithKline Herpes Vaccine Efficacy Study Group.
104. Taranger J., Trollfors B., Bergfors E., Knutsson N., Lagergard T., Schneerson R., Robbins J.B. Immunologic and epidemiologic experience of vaccination with monocomponent pertussis toxoid vaccine. Pediatrics 2001, 108:E115.
105. Tarkowski A., Lue C., Moldoveanu Z., Kiyono H., McGhee J.R., Mestecky J. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J. Immunol. 1990, 144:3770-3778.
106. Wang J.B., Adler S.P., Hempfling S., Burke R.L., Duliege A.M., Starr S.E., Plotkin S.A. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus. J. Infect. Dis. 1996, 174:387-392.
107. Winner L., Mach J., Weltzin R., Mekalanos J.J., Kraehenbuhl J.P., Neutra M.R. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect. Immun. 1991, 59(3):977-982.
108. Woodland D.L. Cell-mediated immunity to respiratory virus infections. Curr. Opin. Immunol. 2003, 15:430-435.
109. Zhang Q., Choo S., Everard J., Jennings R., Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect. Immun. 2000, 68:2692-2697.
110. Zhang Q., Lakshman R., Burkinshaw R., Choo S., Everard J., Akhtar S, Fi A Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect. Immun. 2001, 69:4337-4341.
111. Zhang Q., Pettitt E., Burkinshaw R., Race G., Shaw L., Finn A. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr. Infect. Dis. J. 2002, 21:209-213.